This is a correction to: Richard A Furie, Ian N Bruce, Thomas Dörner, Manuel Gustavo Leon, Piotr Leszczyński, Murray Urowitz, Birgit Haier, Teri Jimenez, Claire Brittain, Jiajun Liu, Catherine Barbey, Christian Stach, Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus, Rheumatology, Volume 60, Issue 11, November 2021, Pages 5397–5407, https://doi.org/10.1093/rheumatology/keab381
In the originally published version of this manuscript, there were a number of incorrect values in the text and text omitted from the Figure 2 legend.
Page 5400:
“83.7, 86.0, 81.8, and 80.4%” should instead read “83.7, 86.0, 79.5, and 80.4%”
Page 5402:
Figure 2 title:
“(E) BILAG 2004 total score” should be followed by footnote c
“(F) cumulative number of severe BILAG flares” should be followed by footnote d
Figure 2 panel E:
Left to right, then top to bottom, the n values should read 43, 43, 44, and 46, instead of 36, 40, 38, and 42.
Figure 2 legend:
“aNonresponder imputation; bMixed model with repeated measures; cBILAG severe flare: new Grade A since the previous visit” should instead read, “aFull analysis set, modified nonresponder imputation using logistic regression; bCompleter set, observed case using mixed model with repeated measures; cFull analysis set, observed cases using ANCOVA; dFull analysis set, observed case, BILAG severe flare: new Grade A since the previous visit.”
Page 5404:
Table 2, column “SOC + DZP 45 mg/kg (n = 47)”, row “Upper respiratory tract infections” should read “13 (27.7) [15]” instead of “40 (29.2) [49]”.
These errors have been corrected online.